Inclusion Criteria:  Have a diagnosis, within 3 years of screening, of previously treated subfoveal neovascularization (SFNV) secondary to nAMD with leakage involving the fovea, previously treated with documented evidence of an initially favorable clinical response to anti-VEGF therapy (i.e. aflibercept, ranibizumab, brolucizumab, or bevacizumab). The macular appearance on OCT is considered to be free of excess intraretinal and/or subretinal fluid as judged by the investigator. Must have received at least 3 anti-VEGF injections in the past year. Have received the most recent anti-VEGF injection within the past 1-4 weeks prior to screening visit. BCVA ETDRS score between 24 and 83 letters (~20/25 to ~20/320 Snellen equivalent)  Exclusion Criteria:  Have evidence of a scar, fibrosis or atrophy of >50% of the total lesion in the study eye Have presence of a disease other than choroidal neovascular membrane (CNVM) due to AMD in the study eye that could affect vision or safety assessments Have monocular vision (fellow eye Snellen BCVA is 20/200 or worse